Of CTCs, EMT, PSA, and megakaryocytes … Huh?

A newly published study in Clinical Cancer Research has implied the potential development of a completely new and much more accurate way to be able to identify risk for metastatic prostate cancer. … READ MORE …

Radio-guided salvage surgery for recurrent prostate cancer

A recent article (in German in Der Urologe) has discussed the early use of PSMA-radio-guided surgery (PSMA-RGS) for targeted resection of localized prostate cancer recurrence. … READ MORE …

A better way to identify risk for metastasis?

According to a news report on the ScienceDaily web site, researchers in the UK have identified a subgroup of circulating tumor cells (CTCs) in patient’s blood that seem to be linked to risk for progression and spread of prostate cancer. … READ MORE …

A new method to use CTCs to diagnose/assess risk for prostate cancer?

In another breaking story from the UK, a company called Angle PLC has announced that its Parsortix diagnostic system can potentially be used to identify men with prostate cancer using a simple blood sample and testing for the presence of circulating tumor cells (CTCs). … READ MORE …

Individualizing precision therapy for advanced prostate cancer

There’s a very interesting article this week on the Hutch News pages of the Fred Hutchinson Cancer Research Center (in Seattle, WA). It addresses the degree to which metastatic prostate cancer may be “tailor-made” for individualized, precision cancer therapy. … READ MORE …

Of liquid biopsies, CTCs, and first-line treatment for mCRPC

A paper to be presented at the Genitourinary Cancers Synposium today, suggests that use of a liquid biopsy and analysis of single circulating tumor cells (CTCs) may be helpful in determining therapy for men with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Liquid biopsies and CTC assays — the scientific progress continues

A paper in the British Journal of Cancer has offered further validation of the potential roles for liquid biopsies and circulating tumor cells (CTCs) in the management of aggressive forms of prostate cancer (and in related clinical trials). … READ MORE …